The effect on survival of continuing chemotherapy to near death

BMC Palliative Care

Volumn 10, Issue , 2011, Pages

  Saito, Akiko M ^a   Landrum, Mary ^b   Neville, Bridget A ^c   Ayanian, John Z ^b,d   Earle, Craig C ^e  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; FEMALE; HOSPICE CARE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICARE; OVERALL SURVIVAL; TERMINAL CARE;

EID: 80053173894     PISSN: None     EISSN: 1472684X     Source Type: Journal    
DOI: 10.1186/1472-684X-10-14     Document Type: Article

References (45)

1. PDQ Cancer Information Summaries: Adult Treatment. The PDQ Editorial Advisory Boards, National Cancer Institute http://www.cancer.gov/cancertopics/ pdq/adulttreatment
2. Treatment for lung cancer. The Lung Cancer Alliance, http://www. lungcanceralliance.org/facing/treatment.html
3. Learn About Cancer. The American Cancer Society, http://www.cancer.org/ docroot/LRN/LRN-0.asp
4. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. Matsuyama R, Reddy S, Smith TJ, J Clin Oncol 2006 24 21 3490 3496 10.1200/JCO.2005.03.6236 16849766 (Pubitemid 46638908)
5. Trends in the aggressiveness of cancer care near the end of life. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC, J Clin Oncol 2004 22 2 315 321 14722041 (Pubitemid 41095097)
6. Do aggressive treatments in the last week of life harm quality of death? Silverman GK, Temel J, Podgurski LM, Paulk ME, Jackson VA, Block SD, Buss MK, Prigerson HG, Program and abstracts of the American Geriatrics Society 2007 Annual Scientific Meeting Seattle, Washington. Abstract P4 2007
7. Early palliative care for patients with metastatic non-small-cell lung cancer. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, et al. N Engl J Med 363 8 733 742
8. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Murillo JR Jr, Koeller J, Oncologist 2006 11 10 1095 1099 10.1634/theoncologist.11-10-1095 17110629 (Pubitemid 44788401)
9. Chemotherapy use among Medicare beneficiaries at the end of life. Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS, Ann Intern Med 2003 138 8 639 643 12693886
10. Chemotherapy may be overused at the end of life. Gottlieb S, BMJ 2001 322 7297 1267 10.1136/bmj.322.7297.1267 11375223
11. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Block S, J Clin Oncol 2003 21 6 1133 1138 10.1200/JCO.2003.03.059 12637481 (Pubitemid 46594144)
12. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC, J Clin Oncol 2001 19 4 1064 1070 11181670 (Pubitemid 32176282)
13. Evaluating claims-based indicators of the intensity of end-of-life cancer care. Earle CC, Neville BA, Landrum MB, Souza JM, Weeks JC, Block SD, Grunfeld E, Ayanian JZ, Int J Qual Health Care 2005 17 6 505 509 10.1093/intqhc/mzi061 15985505 (Pubitemid 41762420)
14. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Zippin C, Lum D, Hankey BF, Cancer 1995 76 11 2343 2350 10.1002/1097-0142(19951201)76:11<2343::AID-CNCR2820761124>3.0. CO;2-# 8635041
15. The Surveillance Research Program, National Cancer Institute, SEER Registries http://seer.cancer.gov/registries/data.html
16. Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. Nattinger AB, McAuliffe TL, Schapira MM, J Clin Epidemiol 1997 50 8 939 945 10.1016/S0895-4356(97)00099-1 9291879 (Pubitemid 27423524)
17. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Charlson ME, Pompei P, Ales KL, MacKenzie CR, J Chronic Dis 1987 40 5 373 383 10.1016/0021-9681(87)90171-8 3558716 (Pubitemid 17055592)
18. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Deyo RA, Cherkin DC, Ciol MA, J Clin Epidemiol 1992 45 6 613 619 10.1016/0895-4356(92)90133-8 1607900
19. Development of a comorbidity index using physician claims data. Klabunde CN, Potosky AL, Legler JM, Warren JL, J Clin Epidemiol 2000 53 12 1258 1267 10.1016/S0895-4356(00)00256-0 11146273 (Pubitemid 32007842)
20. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL, Med Care 2002 40 8 Suppl V19 25
21. Nonparametric estimation from incomplete observations. Kaplan EL, Meier P, J Am Stat Assoc 1958 53 457 481 10.2307/2281868
22. Evaluation of survival data and two new rank order statistics arising in its consideration. Mantel N, Cancer Chemother Rep 1966 50 3 163 170 5910392
23. The central role of the propensity score in observational studies for causal effects. Rosenbaum PR, Rubin DB, Biometrika 1983 70 1 41 55 10.1093/biomet/70.1.41
24. Reducing bias in observational studies using subclassification on the propensity score. Rosenbaum PR, Rubin DB, Journal of American Statistical Association 1984 79 387 516 524 10.2307/2288398
25. Instrumental variables. Bowden RJ, Turkington DA, Cambridge University Press: Cambridge, MA 1984
26. Causal effect of ambulatory specialty care on mortality following myocardial infarction: a comparison of propensity score and instrumental variable analyses. Landrum MB, Ayanian JZ, Health Serv Outcomes Res Method 2001 2 221 245 10.1023/A:1020367111374
27. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. McClellan M, McNeil BJ, Newhouse JP, JAMA 1994 272 11 859 866 10.1001/jama.272.11.859 8078163 (Pubitemid 24282095)
28. Econometrics in outcomes research: the use of instrumental variables. Newhouse JP, McClellan M, Annu Rev Public Health 1998 19 17 34 10.1146/annurev.publhealth.19.1.17 9611610 (Pubitemid 28279922)
29. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ, JAMA 2007 297 3 278 285 10.1001/jama.297.3.278 17227979 (Pubitemid 46143305)
30. Who gets chemotherapy for metastatic lung cancer? Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, Weeks JC, Chest 2000 117 5 1239 1246 10.1378/chest.117.5.1239 10807806 (Pubitemid 30321574)
31. Use of hospitals, physician visits, and hospice care during last six months of life among cohorts loyal to highly respected hospitals in the United States. Wennberg JE, Fisher ES, Stukel TA, Skinner JS, Sharp SM, Bronner KK, BMJ 2004 328 7440 607 10.1136/bmj.328.7440.607 15016692
32. Health service areas for the United States. Makuc DM, Haglund B, Ingram DD, Kleinman JC, Feldman JJ, Vital Health Stat 2 1991 112 1 102 1808847
33. Who is the marginal patient? Understanding instrumental variables estimates of treatment effects. Harris KM, Remler DK, Health Serv Res 1998 33 5 Pt 1 1337 1360 9865223 (Pubitemid 29006391)
34. Epidemiology of cancer in the elderly. Current status and projections for the future. Yancik R, Rays 1997 22 1 Suppl 3 9 9250005 (Pubitemid 27288048)
35. Health Insurance And Spending Among Cancer Patients. Kenneth ET, Howard D, Health Aff 2003 W3.189-W183.198
36. Stage at diagnosis and treatment patterns among older women with breast cancer: an HMO and fee-for-service comparison. Riley GF, Potosky AL, Klabunde CN, Warren JL, Ballard-Barbash R, JAMA 1999 281 8 720 726 10.1001/jama.281.8.720 10052442 (Pubitemid 29113453)
37. Accuracy of Medicare claims data for estimation of cancer incidence and resection rates among elderly Americans. Whittle J, Steinberg EP, Anderson GF, Herbert R, Med Care 1991 29 12 1226 1236 10.1097/00005650-199112000-00005 1745080
38. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, et al. J Clin Oncol 2009 27 9 1394 1400 10.1200/JCO.2008.18.7658 19224850
39. The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. Langer CJ, J Clin Oncol 2009 27 9 1350 1354 10.1200/JCO.2008.20.4859 19224840
40. Resurrecting treatment histories of dead patients: a study design that should be laid to rest. Bach PB, Schrag D, Begg CB, JAMA 2004 292 22 2765 2770 10.1001/jama.292.22.2765 15585737 (Pubitemid 39628256)
41. Looking back from death: the value of retrospective studies of end-of-life care. Earle CC, Ayanian JZ, J Clin Oncol 2006 24 6 838 840 10.1200/JCO.2005.03.9388 16484691 (Pubitemid 46638831)
42. Identification in administrative databases of women dying of breast cancer. Gagnon B, Mayo NE, Laurin C, Hanley JA, McDonald N, J Clin Oncol 2006 24 6 856 862 10.1200/JCO.2005.02.1790 16484694 (Pubitemid 46638836)
43. Towards using administrative databases to measure population-based indicators of quality of end-of-life care: testing the methodology. Grunfeld E, Lethbridge L, Dewar R, Lawson B, Paszat LF, Johnston G, Burge F, McIntyre P, Earle CC, Palliat Med 2006 20 8 769 777 10.1177/0269216306072553 17148531 (Pubitemid 46040128)
44. A systematic review of physicians' survival predictions in terminally ill cancer patients. Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, Christakis N, BMJ 2003 327 7408 195 10.1136/bmj.327.7408.195 12881260
45. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology, J Clin Oncol 1996 14 2 671 679 8636786